We were intrigued by the possibility of depleting BCL6 from cancercells and recently reported the degrader CCT369260, capableof degrading tumoral BCL6 in vivo in lymphoma xenograftmouse models.14 However, the high unboundclearance and modest bioavailability of this compound limited itsutility in repeated-dose tumor efficacy models. This evidence concerns the gene BCL6 and neoplasm.